180 Life Sciences Corp.
ATNF
$1.07
-$0.01-0.93%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 91.85% | 100.32% | 77.54% | 94.36% | 52.22% |
| Total Depreciation and Amortization | -57.49% | -16.08% | 8.26% | -39.63% | 308.75% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -100.28% | -125.13% | -53.12% | -96.90% | -59.32% |
| Change in Net Operating Assets | -43.48% | 39,447.62% | -161.02% | -174.13% | 616.48% |
| Cash from Operations | 87.40% | 123.33% | 73.30% | 26.20% | 50.63% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -8.63% | -- |
| Total Debt Repaid | -84.82% | -2.79% | 43.61% | -50.97% | 46.58% |
| Issuance of Common Stock | -100.00% | -100.00% | -- | -86.15% | -53.85% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 87.67% | 44.34% |
| Cash from Financing | -119.46% | -110.76% | 43.72% | -77.04% | -55.41% |
| Foreign Exchange rate Adjustments | -1,321.47% | -52.94% | -112.66% | 105.60% | -124.55% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -245.50% | 173.76% | 69.94% | -120.31% | -66.70% |
